CNP 104
Alternative Names: CNP-104Latest Information Update: 22 May 2024
At a glance
- Originator Cour Pharmaceutical Development
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Primary biliary cirrhosis
Most Recent Events
- 09 May 2024 Ironwood Pharmaceuticals completes enrolment in its phase II trial for Primary biliary cholangitis in USA
- 13 Sep 2022 Phase-II clinical trials in Primary biliary cirrhosis in USA (IV) (Cour Pharmaceutical Development pipeline; September 2022)
- 25 Jan 2022 Phase-I/II clinical trials in Primary biliary cirrhosis in USA (IV) (NCT05104853)